查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1714705

動物疫苗市場按產品類型、動物種類、給藥途徑、疾病類型和分銷管道分類－2025-2030 年全球預測

Veterinary Vaccines Market by Product Type, Animal Type, Route Of Administration, Disease Type, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年獸用疫苗市場價值將達到132.9億美元，2024年將達到141.3億美元，複合年成長率為6.68%，到2030年將達到209.2億美元。

主要市場統計數據
基準年2023年 132.9億美元
預計2024年 141.3億美元
預測年份 2030 209.2億美元
複合年成長率（%） 6.68%

在生物技術進步、對動物疾病的深入了解以及消費者期望不斷提高的推動下，獸用疫苗市場已成為更廣泛的動物保健領域中的一個重要領域。本執行摘要對當前市場動態、新興趨勢和競爭格局進行了深入分析，這些將影響疫苗開發、分銷和管理的未來。隨著全球對高品質、有效獸用疫苗的需求不斷增加，相關人員面臨著法規變化、疾病概況演變以及預防重於治療的日益重視所帶來的機會和挑戰。

在當今的競爭環境中，決策者不僅需要對當前的市場結構有清晰的評估，還需要對變革有前瞻性的觀點。本書揭示了市場創新和技術進步如何與社會經濟動態結合，創造動物健康和福利的新典範。該報告旨在為行業專業人士、投資者和政策制定者提供可行的見解，以實現戰略決策並促進這一不斷發展的行業的永續成長。

各組織越來越意識到需要平衡產品創新和成本效益，以確保獲得疫苗，同時保持不妥協的功效和安全標準。在此背景下，本報告結合了強大的市場研究和細緻的定性見解，為相關人員說明了可導航的、複雜的獸用疫苗格局。

改變動物疫苗市場

過去十年，獸用疫苗產業經歷了深刻變革時期，市場格局也發生了變化。尖端調查方法、數位轉型和製造流程改進如今在引導產品創新方面發揮關鍵作用。基因組定序和免疫學資料分析等下一代技術的整合使製造商能夠加速開發具有更好療效的疫苗。

該市場的法律規範也正在經歷巨大變革。隨著各國實施更嚴格的安全和功效標準，製造商被迫在研發和品管系統上投入大量資金。這就創造了這樣一種局面：少數現任者將率先取得進展，不僅透過改進現有的疫苗配方，而且還透過探索針對更廣泛病原體的新作用機制。此外，全球對動物福利、食品安全和公共衛生的重視使得人們重新關注預防措施，而不是簡單地治療現有症狀。

這種轉變的另一個特點是市場營運中擴大採用數位平台。從改進的資料收集方法來追蹤疾病趨勢，到提高分銷效率的數位供應鏈管理系統，技術正成為市場競爭力的基石。這些進步有助於做出更明智的決策，使相關人員能夠最大限度地降低風險並最佳化資源配置。此外，跨學科研究和跨部門夥伴關係的整合正在產生創新的疫苗接種系統，改善偏遠和服務不足社區的疫苗接種服務。

隨著市場動態的不斷發展，行業專家預測，重點將繼續放在將技術與對當地市場需求的深入了解相結合的擴充性解決方案上。這些趨勢的融合將開啟一個更緊密合作、疫苗開發更靈活的時代，最終改善全世界的動物健康。

動物疫苗的關鍵細分洞察

詳細了解市場區隔可以為推動動物疫苗市場成長和多樣化的因素提供關鍵見解。基於產品類型的分析揭示了市場如何研究頻譜疫苗技術，包括去活化疫苗、減毒活病毒疫苗、次單位疫苗和重組疫苗以及病毒載體疫苗。每個類別都有不同的優勢，並針對動物健康的不同方面，從而可以採取有針對性的方法來應對獨特的經濟和監管挑戰。這些領域的快速創新不僅提高了疫苗效力，也增強了消費者信心和市場滲透率。

此外，根據動物類型細分，市場分為伴侶動物和農場動物。人們對伴同性動物（尤其是狗和貓）的關注是由於人們對寵物人性化的日益成長的趨勢以及寵物醫療保健支出的增加。相較之下，以牲畜為重點的領域則將牛、雞、羊和豬視為重要市場。這種二分法凸顯了需要客製化疫苗配方，以解決每個群體中不同的病原體特徵和疾病動態。除了產品差異化之外，這種細分方法還提供了一個實用的框架，用於理解購買模式、區域需求以及各個子區隔背後的經濟驅動力。

從給藥途徑的角度分析市場表明，已經開發了口服、腸胃外和局部方法來滿足特定的臨床和後勤需求。這種差異化對於推動疫苗接種和確保從商業農場到小型動物診所等各種環境下的合規性至關重要。此外，基於疾病類型的細分可以深入了解市場促進因素。市場進一步分解為細菌感染、真菌感染、寄生蟲感染、病毒感染，並透過梭菌、大腸桿菌、鉤端螺旋體病、巴氏桿菌症病等次維度研究細菌感染。寄生蟲感染主要集中在體外寄生蟲和體內寄生蟲。另一方面，我們透過評估禽流感病毒、牛病毒性腹瀉病毒、口蹄疫病毒、新城疫病毒、豬繁殖與呼吸綜合症病毒和狂犬病毒等生物體的威脅，採取綜合措施應對病毒感染。

最後，從分銷管道的角度來看，市場動態變得更加微妙。透過調查網路藥局、零售藥局和獸醫診所，可以深入了解疫苗到達最終用戶的不斷變化的方法。這種分銷細分凸顯了傳統和數位方法的策略整合，以有效滿足多樣化的客戶群。摘要：多方面的細分不僅增強了對市場力量的理解，而且還為相關人員提供了可操作的資訊，以微調他們的產品供應、業務戰略和長期市場定位。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 牲畜感染疾病率不斷上升
      • 隨著寵物醫療保健支出的增加，全球範圍內的寵物擁有量也在增加
      • 政府對獸醫保健的措施和認知
    • 限制因素
      • 開發和儲存動物疫苗的高成本
    • 機會
      • 疫苗技術創新以提高疫苗效力和安全性
      • 研究與政府夥伴關係推動獸用疫苗研發
    • 任務
      • 對獸用疫苗產品召回的擔憂
      • 圍繞獸用疫苗的嚴格法規結構
  • 市場區隔分析
    • 產品類型：增加減毒活疫苗在獸醫學中的使用，以平衡療效和安全性
    • 動物類型：羊疫苗研發進展，確保綿羊健康與生產力
    • 給藥途徑：抗原穩定性和遞送技術的進步促使獸醫採用口服疫苗
    • 疾病類型：針對體外寄生蟲的疫苗正在開發中，作為化療的有效替代品。
    • 分銷管道：數位革命和人工智慧驅動的個人化疫苗推薦正在推動線上藥局的需求
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章動物疫苗市場（依產品類型）

  • 去活化疫苗
  • 減毒活疫苗
  • 次單位疫苗和重組疫苗
  • 病毒載體疫苗

7. 動物疫苗市場（依動物類型）

  • 伴同性動物
    • 貓
    • 狗
  • 家畜
    • 牛
    • 家禽
    • 羊
    • 豬

第8章動物疫苗市場（依給藥途徑）

  • 口服
  • 腸外
  • 話題

第9章動物疫苗市場（依疾病類型）

  • 細菌感染疾病
    • 梭菌
    • 大腸桿菌
    • 鉤端螺旋體病
    • 巴氏桿菌
  • 黴菌感染疾病
  • 寄生蟲感染疾病
    • 體外寄生蟲
    • 體內寄生蟲
  • 病毒感染
    • 禽流感病毒
    • 牛病毒性腹瀉病毒（BVDV）
    • 口蹄疫病毒（FMDV）
    • 新城疫病毒
    • 豬繁殖與呼吸綜合症病毒（PRRSV）
    • 狂犬病毒

第 10 章動物疫苗市場（依通路）

  • 網路藥局
  • 零售藥局
  • 獸醫診所

第 11 章：美洲動物疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太動物疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13. 歐洲、中東和非洲動物疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023年市場佔有率分析
  • 2023年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Arko Corp.
  • Bimeda Biologicals Inc
  • Biogenesis Bago SA
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Endovac Animal Health
  • Hester Biosciences Limited
  • Hipra SA
  • Huvepharma, Inc.
  • Indian Immunologicals Ltd.
  • Kemin Industries, Inc.
  • Merck & Co., Inc.
  • Neogen Corporation
  • Pfizer, Inc.
  • Phibro Animal Health Corporation
  • SAN Group Biotech Germany GmbH
  • Seppic by Air Liquide Healthcare
  • SK Bioscience
  • Vaxxinova
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-4316E4E89380

The Veterinary Vaccines Market was valued at USD 13.29 billion in 2023 and is projected to grow to USD 14.13 billion in 2024, with a CAGR of 6.68%, reaching USD 20.92 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 13.29 billion
Estimated Year [2024] USD 14.13 billion
Forecast Year [2030] USD 20.92 billion
CAGR (%) 6.68%

The veterinary vaccines market has emerged as a crucial segment within the broader animal healthcare landscape, driven by advancements in biotechnology, enhanced understandings of animal diseases, and evolving consumer expectations. This executive summary provides an in-depth analysis of the current market dynamics, emerging trends, and the competitive environment that is shaping the future of vaccine development, distribution, and administration. As the global demand for high-quality and effective veterinary vaccines increases, stakeholders are facing both opportunities and challenges spurred on by regulatory shifts, evolving disease profiles, and a growing emphasis on prevention over treatment.

In today's competitive environment, decision-makers require not only a clear assessment of current market structures but also a forward-looking perspective on transformative shifts. The narrative presented herein elucidates how market innovations and technological advancements, coupled with socio-economic dynamics, are crafting a new paradigm in animal health and well-being. The objective of this report is to furnish industry professionals, investors, and policy-makers with actionable insights that can enable strategic decision making and foster sustainable growth in an ever-evolving field.

Organizations are increasingly recognizing the critical need to balance product innovation with cost-effectiveness, ensuring that vaccines remain accessible while upholding uncompromising efficacy and safety standards. Against this backdrop, the report synthesizes robust market research with nuanced qualitative insights to guide stakeholders through the complexities of the veterinary vaccines landscape.

Transformative Shifts in the Veterinary Vaccines Landscape

Over the past decade, the veterinary vaccines industry has experienced significant transformative shifts that are reshaping the market environment. State-of-the-art research methodologies, digital transformation, and improved manufacturing processes now play a vital role in steering product innovation. The integration of next-generation technologies such as genomic sequencing and immunological data analytics has allowed manufacturers to develop vaccines with better efficacy profiles at an accelerated pace.

The market is also witnessing a dramatic evolution in regulatory frameworks. As countries tighten safety and efficacy standards, manufacturers are compelled to invest substantially in R&D and quality management systems. This has led to a scenario where a few established players are spearheading advancements, not only by improving existing vaccine formulations but also by exploring novel mechanisms of action that target a broader spectrum of pathogens. Moreover, the global emphasis on animal welfare, food security, and public health has fueled a renewed focus on preventative measures rather than merely treating existing conditions.

Another hallmark of these shifts is the increasing adoption of digital platforms in market operations. From enhanced data collection methods that track disease trends to digital supply chain management systems that increase distribution efficiency, technology is becoming the cornerstone of market competitiveness. These advancements are facilitating more informed decision-making, allowing stakeholders to minimize risks and optimize resource allocation. Additionally, the confluence of interdisciplinary research and cross-industry partnerships is spawning innovative vaccine delivery systems and improving accessibility to remote and underserved areas.

As market dynamics continue to evolve, industry experts predict a sustained focus on scalable solutions that integrate technology with a deep understanding of local market needs. The convergence of these trends is setting the stage for an era of heightened collaboration and a more agile approach to vaccine development, ultimately leading to improved animal health outcomes across the globe.

Key Segmentation Insights in Veterinary Vaccines

A granular understanding of market segmentation reveals critical insights into the factors underpinning the growth and diversification of the veterinary vaccines market. Analyses based on product type reveal how the market is studied across a spectrum of vaccine technologies which include inactivated vaccines, live attenuated vaccines, subunit and recombinant vaccines, and viral vector vaccines. Each category offers distinct advantages and caters to various segments of animal health, enabling targeted approaches that meet unique economic and regulatory challenges. The rapid innovation in these areas has not only increased the effectiveness of vaccines but also sparked increased consumer trust and market penetration.

Furthermore, segmentation based on animal type delineates the market into companion and livestock animals. The focus on companion animals, notably cats and dogs, is driven by the growing trend of pet humanization and increased expenditures on pet healthcare. In contrast, the segment focusing on livestock animals highlights cattle, poultry, sheep, and swine as critical markets. This dichotomy underscores the need for tailored vaccine formulations that address distinct pathogen profiles and disease dynamics prevalent in each group. In addition to product differentiation, this segmentation approach offers a pragmatic framework for understanding purchasing patterns, regional demand, and the economic drivers underpinning various sub-segments.

When analyzing the market from the perspective of the route of administration, it becomes evident that the methods - oral, parenteral, and topical - are developed to meet specific clinical and logistical needs. This differentiation is crucial in enhancing vaccine uptake and ensuring compliance across different environments, from commercial farms to small animal clinics. Moreover, segmentation based on disease type offers an intricate view of market drivers. The market is further dissected into bacterial infections, fungal infections, parasitic infections, and viral infections, with bacterial infections being studied through sub-dimensions such as clostridial, E. coli, leptospirosis, and pasteurella challenges. For parasitic infections, the focus spans both ectoparasites and endoparasites, whereas viral infections are comprehensively approached by evaluating threats posed by organisms including avian influenza virus, bovine viral diarrhea virus, foot-and-mouth disease virus, Newcastle disease virus, porcine reproductive and respiratory syndrome virus, and rabies virus.

Finally, when viewed in terms of distribution channels, the market dynamics become even more nuanced. The examination of online pharmacies, retail pharmacies, and veterinary clinics provides insights into the evolving methodologies through which vaccines reach their end-users. This distribution segmentation underlines a strategic consolidation of both traditional and digital avenues to efficiently cater to a diverse clientele. In summary, the multi-dimensional segmentation not only enhances the understanding of market forces but also equips stakeholders with actionable intelligence to fine-tune their product offerings, operational strategies, and long-term market positioning.

Based on Product Type, market is studied across Inactivated Vaccines, Live Attenuated Vaccines, Subunit & Recombinant Vaccines, and Viral Vector Vaccines.

Based on Animal Type, market is studied across Companion Animals and Livestock Animals. The Companion Animals is further studied across Cats and Dogs. The Livestock Animals is further studied across Cattle, Poultry, Sheep, and Swine.

Based on Route Of Administration, market is studied across Oral, Parenteral, and Topical.

Based on Disease Type, market is studied across Bacterial Infections, Fungal Infections, Parasitic Infections, and Viral Infections. The Bacterial Infections is further studied across Clostridial, E. Coli, Leptospirosis, and Pasteurella. The Parasitic Infections is further studied across Ectoparasites and Endoparasites. The Viral Infections is further studied across Avian Influenza Virus, Bovine Viral Diarrhea Virus (BVDV), Foot-and-Mouth Disease Virus (FMDV), Newcastle Disease Virus, Porcine Reproductive & Respiratory Syndrome Virus (PRRSV), and Rabies Virus.

Based on Distribution Channel, market is studied across Online Pharmacies, Retail Pharmacies, and Veterinary Clinics.

Regional Insights Shaping the Veterinary Vaccines Market

Regional dynamics continue to play a pivotal role in the growth and sustainability of the veterinary vaccines market. The Americas, characterized by extensive industrial livestock farming and high veterinary standards, set the stage for robust market expansion driven by a blend of advanced infrastructure and a strong regulatory environment. The emphasis on technological investments in modern vaccine production facilities and extensive preventative measures contributes to the steady evolution of the market across North and South America.

Europe, Middle East & Africa, on the other hand, presents a complex yet promising landscape where regulatory stringency often meets diverse market challenges. In regions where animal husbandry forms a critical component of the agricultural economy, there is a significant thrust towards ensuring that vaccines are both effective and economically viable. The continuous efforts to align regional health standards with global best practices have spurred investments in innovative vaccine solutions, while efforts to address zoonotic risks have further accelerated regional collaborations.

Asia-Pacific remains one of the fastest growing regions in this market, fueled by rapid economic development, increased pet ownership, and evolving livestock rearing practices. Investments in veterinary healthcare infrastructure coupled with escalating public awareness campaigns are paving the way for substantial market growth. The heterogeneous nature of the region, which includes both technologically advanced centers and emerging economies, further emphasizes the need for customized approaches in vaccine development and distribution. In each of these regions, socio-economic factors, government policies, and local disease prevalence play crucial roles in influencing market trends and investment decisions.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New Jersey, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Company Strategies Impacting the Market

The competitive landscape of the veterinary vaccines market is marked by a number of key industry players, each driving the market through a mix of innovation, strategic acquisitions, and robust research pipelines. Leading companies such as Arko Corp. and Bimeda Biologicals Inc are forging strong partnerships and leveraging their deep-rooted expertise to expand their market presence across diverse geographies. Companies like Biogenesis Bago S.A. are increasingly investing in novel techniques in vaccine formulation to enhance efficacy and minimize adverse reactions, setting new benchmarks in the industry.

Boehringer Ingelheim International GmbH and Ceva Sante Animale continue to push the envelope on research and development, enabling them to capture significant market share by addressing complex health challenges across both companion and livestock segments. Similarly, Dechra Pharmaceuticals PLC and Elanco Animal Health Incorporated are known for their strategic investments in state-of-the-art production facilities, which not only optimize production efficiency but also ensure compliance with evolving global standards. Endovac Animal Health and Hester Biosciences Limited are successfully navigating niche market segments by addressing specific regional and disease-based demands.

Certain companies such as Hipra S.A. and Huvepharma, Inc. are notably active in exploring the intersections of technology and animal health, thereby creating innovative vaccine delivery systems that resonate well in both urban and rural settings. Indian Immunologicals Ltd. and Kemin Industries, Inc. have made significant strides in penetrating emerging markets through tailored product portfolios that address region-specific challenges. Meanwhile, global giants including Merck & Co., Inc. and Neogen Corporation have maintained their leadership status by forging strategic alliances and integrating advanced digital capabilities into their business models.

Pfizer, Inc. and Phibro Animal Health Corporation, as well as SAN Group Biotech Germany GmbH, have been instrumental in carving out a niche in specialized vaccine segments, particularly those addressing zoonotic diseases and high-impact infections. Companies such as Seppic by Air Liquide Healthcare, SK Bioscience, Vaxxinova, Virbac S.A., and Zoetis Inc. round out a competitive landscape that is characterized by aggressive innovation strategies, robust clinical testing, and an unwavering commitment to elevating animal health standards. This constellation of market leaders not only shapes current industry practices but also sets the tone for future market trends and innovations.

The report delves into recent significant developments in the Veterinary Vaccines Market, highlighting leading vendors and their innovative profiles. These include Arko Corp., Bimeda Biologicals Inc, Biogenesis Bago S.A., Boehringer Ingelheim International GmbH, Ceva Sante Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health Incorporated, Endovac Animal Health, Hester Biosciences Limited, Hipra S.A., Huvepharma, Inc., Indian Immunologicals Ltd., Kemin Industries, Inc., Merck & Co., Inc., Neogen Corporation, Pfizer, Inc., Phibro Animal Health Corporation, SAN Group Biotech Germany GmbH, Seppic by Air Liquide Healthcare, SK Bioscience, Vaxxinova, Virbac S.A., and Zoetis Inc.. Actionable Recommendations for Industry Leaders

To effectively navigate the rapidly evolving veterinary vaccines landscape, industry leaders are advised to pursue a multifaceted strategy that spans innovation, collaboration, and market adaptation. It is imperative to invest in emerging technologies that streamline vaccine development. By harnessing the latest advancements in biotechnology, manufacturers can improve vaccine efficacy, reduce production timelines, and enhance the safety profiles of their products. Incorporating data analytics and genomics provides a roadmap for more targeted vaccine development, ensuring that solutions are both effective and adaptable to the unique challenges of different animal populations.

A strategic focus on research and development should be prioritized, with a particular emphasis on partnerships that bridge the gap between academic research and practical application. Collaborative efforts can drive breakthrough innovations that not only address well-known pathogens but also anticipate emerging threats. Additionally, diversifying product portfolios to include a range of vaccine types-from inactivated and live attenuated to subunit, recombinant, and viral vector vaccines-can help stakeholders cater to varied market demands, thereby ensuring resiliency in the face of changing disease dynamics.

Furthermore, market leaders should explore tailor-made strategies for different animal types and routes of administration. For instance, shaping products for companion animals such as cats and dogs requires an understanding of consumer trends and lifestyle changes, while the livestock segment demands cost-effective solutions that can be deployed on a large scale. Extending these innovations to address a comprehensive spectrum of diseases-from bacterial and fungal to parasitic and viral infections-will be critical to meeting market needs. In particular, detailed insights into the specific pathogens and challenges associated with each disease category should influence product design and delivery methods.

In addition to enhancing product portfolios, the adoption of an omni-channel distribution strategy that includes online and retail pharmacies as well as veterinary clinics can further drive market reach and penetration. Understanding customer behaviors and adapting to digital trends will be pivotal in ensuring that vaccines are accessible to a broader spectrum of end-users. Finally, industry leaders must remain agile by continuously monitoring regulatory developments, investing in quality assurance, and refining operational efficiencies. This proactive approach will not only address market fluctuations but also position organizations to seize new opportunities as they emerge.

Conclusion: Navigating the Veterinary Vaccines Sector

In summary, the veterinary vaccines market stands at a pivotal crossroads marked by innovation, regulatory rigor, and dynamic consumer behavior. The current landscape is defined by a blend of traditional manufacturing practices and revolutionary technological interventions that together are fostering a more robust and responsive vaccine ecosystem. The in-depth analysis provided in this report highlights the importance of understanding segmented market demands-ranging from the nuances of product types and animal classifications to the subtleties in administration routes and disease-specific strategies. Each segmentation axis offers valuable insights that inform both the strategic direction and operational execution necessary for success in this competitive arena.

The integration of diverse regional insights further underscores the global nature of the challenges and opportunities present in the veterinary vaccines market. Regions such as the Americas, Europe, Middle East & Africa, and Asia-Pacific contribute distinct perspectives and requirements, demanding versatile approaches that align with local realities while adhering to universal standards of excellence. Similarly, key players in the market continue to drive progress through robust research initiatives and strategic investments, setting a precedent for how innovation and collaboration can propel the industry forward.

As organizations move ahead, the convergence of science and technology with market-specific insights will be crucial in devising solutions that are not only effective in disease prevention but also sustainable in the long run. Ultimately, the future of the veterinary vaccines market depends on the ability of industry leaders to adapt to emerging trends, capitalize on segmentation insights, and consistently deliver high-quality products that protect animal health and, by extension, the broader public health landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased incidences of infectious diseases in livestock
      • 5.1.1.2. Growing pet ownership worldwide with increased spending on pet healthcare
      • 5.1.1.3. Government initiatives and awareness for veterinary healthcare
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with the development and storage of veterinary vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations in vaccine technology to enhance vaccine efficacy and safety
      • 5.1.3.2. Partnerships between research institutes and governmental agencies for advancing veterinary vaccine
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with product recall of veterinary-vaccines
      • 5.1.4.2. Stringent regulatory frameworks associated with veterinary vaccines
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Rising usage of live attenuated vaccines for balancing efficacy and safety in veterinary medicine
    • 5.2.2. Animal Type: Advancements in sheep vaccination ensuring flock health and productivity
    • 5.2.3. Route Of Administration: Adoption of oral vaccine in veterinary medicine due to advancements for stability and delivery of antigens
    • 5.2.4. Disease Type: Increasing development of a vaccine against ectoparasites for an efficient alternative to chemical treatments
    • 5.2.5. Distribution Channel: Growing demand for online pharmacies due to the digital revolution and AI to recommend personalized vaccine
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Veterinary Vaccines Market, by Product Type

  • 6.1. Introduction
  • 6.2. Inactivated Vaccines
  • 6.3. Live Attenuated Vaccines
  • 6.4. Subunit & Recombinant Vaccines
  • 6.5. Viral Vector Vaccines

7. Veterinary Vaccines Market, by Animal Type

  • 7.1. Introduction
  • 7.2. Companion Animals
    • 7.2.1. Cats
    • 7.2.2. Dogs
  • 7.3. Livestock Animals
    • 7.3.1. Cattle
    • 7.3.2. Poultry
    • 7.3.3. Sheep
    • 7.3.4. Swine

8. Veterinary Vaccines Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral
  • 8.4. Topical

9. Veterinary Vaccines Market, by Disease Type

  • 9.1. Introduction
  • 9.2. Bacterial Infections
    • 9.2.1. Clostridial
    • 9.2.2. E. Coli
    • 9.2.3. Leptospirosis
    • 9.2.4. Pasteurella
  • 9.3. Fungal Infections
  • 9.4. Parasitic Infections
    • 9.4.1. Ectoparasites
    • 9.4.2. Endoparasites
  • 9.5. Viral Infections
    • 9.5.1. Avian Influenza Virus
    • 9.5.2. Bovine Viral Diarrhea Virus (BVDV)
    • 9.5.3. Foot-and-Mouth Disease Virus (FMDV)
    • 9.5.4. Newcastle Disease Virus
    • 9.5.5. Porcine Reproductive & Respiratory Syndrome Virus (PRRSV)
    • 9.5.6. Rabies Virus

10. Veterinary Vaccines Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies
  • 10.4. Veterinary Clinics

11. Americas Veterinary Vaccines Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Veterinary Vaccines Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Veterinary Vaccines Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Boehringer Ingelheim introduces advanced poultry vaccine in India
    • 14.3.2. Ceva Animal Health's innovative expansion with new vaccine manufacturing plant in Hungary
    • 14.3.3. Ceva unveils BLUEVAC-3 to combat bluetongue virus in the UK
    • 14.3.4. Researchers developed a vaccine to protect cattle from bovine anaplasmosis
    • 14.3.5. USDA launches oral rabies vaccination program in eastern U.S. to combat wildlife rabies spread
    • 14.3.6. Merck Animal Health acquires Elanco's aqua business
    • 14.3.7. Botswana Vaccine Institute collaborates with Techinvention Lifecare to increase veterinary vaccine production
    • 14.3.8. Penn Vet's pioneering mRNA research initiative to enhance veterinary vaccine development
    • 14.3.9. Huvepharma's conditional USDA approval for groundbreaking turkey coccidiosis vaccine
    • 14.3.10. LSU's innovative bovine respiratory vaccine saves the cattle industry
    • 14.3.11. U.S.-African Union partnership fortifies veterinary vaccine infrastructure in Ethiopia
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. Boehringer Ingelheim International GmbH
    • 14.4.2. Virbac SA
    • 14.4.3. Merck & Co., Inc
    • 14.4.4. Zoetis Inc.

Companies Mentioned

  • 1. Arko Corp.
  • 2. Bimeda Biologicals Inc
  • 3. Biogenesis Bago S.A.
  • 4. Boehringer Ingelheim International GmbH
  • 5. Ceva Sante Animale
  • 6. Dechra Pharmaceuticals PLC
  • 7. Elanco Animal Health Incorporated
  • 8. Endovac Animal Health
  • 9. Hester Biosciences Limited
  • 10. Hipra S.A.
  • 11. Huvepharma, Inc.
  • 12. Indian Immunologicals Ltd.
  • 13. Kemin Industries, Inc.
  • 14. Merck & Co., Inc.
  • 15. Neogen Corporation
  • 16. Pfizer, Inc.
  • 17. Phibro Animal Health Corporation
  • 18. SAN Group Biotech Germany GmbH
  • 19. Seppic by Air Liquide Healthcare
  • 20. SK Bioscience
  • 21. Vaxxinova
  • 22. Virbac S.A.
  • 23. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. VETERINARY VACCINES MARKET MULTI-CURRENCY
  • FIGURE 2. VETERINARY VACCINES MARKET MULTI-LANGUAGE
  • FIGURE 3. VETERINARY VACCINES MARKET RESEARCH PROCESS
  • FIGURE 4. VETERINARY VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL VETERINARY VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. VETERINARY VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. VETERINARY VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VETERINARY VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VETERINARY VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VETERINARY VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DOGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CATTLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY VACCINES MARKET SIZE, BY POULTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SHEEP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY VACCINES MARKET SIZE, BY SWINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY VACCINES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY VACCINES MARKET SIZE, BY E. COLI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PASTEURELLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ECTOPARASITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ENDOPARASITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RABIES VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES VETERINARY VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 171. JAPAN VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 172. JAPAN VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 181. MALAYSIA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 182. MALAYSIA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 183. MALAYSIA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 192. PHILIPPINES VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. SINGAPORE VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 201. SINGAPORE VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 202. SINGAPORE VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 203. SINGAPORE VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH KOREA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH KOREA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. TAIWAN VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. TAIWAN VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 221. TAIWAN VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 222. TAIWAN VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 223. TAIWAN VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. THAILAND VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. THAILAND VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 231. THAILAND VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 232. THAILAND VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 233. THAILAND VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 239. VIETNAM VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. VIETNAM VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 241. VIETNAM VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 242. VIETNAM VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 243. VIETNAM VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 260. DENMARK VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. DENMARK VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 262. DENMARK VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 263. DENMARK VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 264. DENMARK VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 270. EGYPT VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. EGYPT VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 272. EGYPT VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 273. EGYPT VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 274. EGYPT VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 280. FINLAND VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. FINLAND VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 282. FINLAND VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 283. FINLAND VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 284. FINLAND VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 290. FRANCE VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. FRANCE VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 292. FRANCE VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 293. FRANCE VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 294. FRANCE VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 298. GERMANY VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 300. GERMANY VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. GERMANY VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 302. GERMANY VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 303. GERMANY VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 304. GERMANY VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 308. ISRAEL VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 310. ISRAEL VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. ISRAEL VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 312. ISRAEL VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 313. ISRAEL VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 314. ISRAEL VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 315. ITALY VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 316. ITALY VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. ITALY VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 318. ITALY VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 320. ITALY VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. ITALY VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 322. ITALY VETERINARY VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 323. ITALY VETERINARY VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 324. ITALY VETERINARY VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS VETERINARY VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. NETHERLANDS VETERINARY VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS VETERINARY VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 328. NETHERLANDS VETERINARY VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS VETERINARY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 330. NETHERLANDS VETERINARY VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS VETERINARY VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILL